Predicting radiation lung inflammation in people with lung cancer treated with immunotherapy
Builds a model to predict radiation lung inflammation in adults with lung cancer.
Key facts
- Who runs it
- HAN GUANG
- Where
- Wuhan, ChinaSee the site
- Trial code
- Registry title
- Multi-Omics Prediction of Radiation Lung Injury in Immunotherapy-Treated Lung Cancer Patients
- Status
- Not yet recruiting
- People taking part
- 160 people, planned
- Started
- 15 Aug 2026
- Expected to end
- 15 Aug 2028
- Type of study
- Observational
- Treatments tested
- No Intervention: Observational Cohort
- Record updated
- 3 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with lung cancer (non-small cell or small cell) who had immunotherapy with a PD-1 drug and are now getting radiotherapy to the chest. It studies who develops lung inflammation from radiation.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Lung cancer (NSCLC or SCLC). Life expectancy of at least 6 months. Zubrod performance status of 0-1.
- Earlier treatment
- Must have had at least 2 cycles of PD-1 systemic therapy, alone or combined, within the past six months. Chest CT scan taken before immunotherapy started. Chest radiotherapy dose of 30Gy or more. No antibiotics in the week before radiotherapy starts.
Main reasons for not taking part
- Taking part in other interventional studies or treatments
- Investigational drugs or treatments within 4 weeks before the first dose
- Earlier solid organ or hematopoietic stem cell transplant
- Active infection
- Existing or active pneumonitis caused by immunotherapy (ICI)
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Patients aged 18 or older years with a life expectancy of at least 6 months. Additional inclusion criteria were a Zubrod performance status of 0-1, documentation of baseline chest computed tomography (CT) scans prior to the initiation of immunotherapy, receipt of at least 2 cycles of systemic therapy (PD-1) as either monotherapy or combination therapy within the past six months, voluntary participation with written informed consent, and appropriate baseline biochemical tests. The radiation dose for thoracic radiotherapy was ≥30Gy for all eligible patients in this study. No use of antibiotics within 1 week prior to the initiation of thoracic radiotherapy
Who cannot take part
- -
Where in China
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaContact: Guang HanNo longer taking part
About the trial
What the trial wants to find out
This prospective study aims to develop a multi-omics-based predictive model for radiation pneumonitis in lung cancer patients receiving sequential immunotherapy and thoracic radiotherapy.
The group in the trial
- Lung Cancer Patients Receiving Sequential Immunotherapy and Thoracic Radiotherapy
Treatment: No Intervention: Observational Cohort
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Multi-Omics Prediction of Radiation Pneumonitis Risk in Lung Cancer Patients After Immunotherapy and Thoracic Radiotherapy
- Plain-language title
- Predicting radiation lung inflammation in people with lung cancer treated with immunotherapyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 3 August 2026